{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:33:23Z","timestamp":1778646803282,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006352","name":"Virginia and D.K. Ludwig Fund for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"EIF | Stand Up To Cancer","doi-asserted-by":"publisher","award":["3.1416"],"award-info":[{"award-number":["3.1416"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA248384"],"award-info":[{"award-number":["P01 CA248384"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Leukemias and their bone marrow microenvironments undergo dynamic changes over the course of disease. However, little is known about the circulation kinetics of leukemia cells, nor the impact of specific factors on the clearance of circulating leukemia cells (CLCs) from the blood. To gain a basic understanding of CLC dynamics over the course of disease progression and therapeutic response, we apply a blood exchange method to mouse models of acute leukemia. We find that CLCs circulate in the blood for 1\u20132 orders of magnitude longer than solid tumor circulating tumor cells. We further observe that: (i) leukemia presence in the marrow can limit the clearance of CLCs in a model of acute lymphocytic leukemia (ALL), and (ii) CLCs in a model of relapsed acute myeloid leukemia (AML) can clear faster than their untreated counterparts. Our approach can also directly quantify the impact of microenvironmental factors on CLC clearance properties. For example, data from two leukemia models suggest that E-selectin, a vascular adhesion molecule, alters CLC clearance. Our research highlights that clearance rates of CLCs can vary in response to tumor and treatment status and provides a strategy for identifying basic processes and factors that govern the kinetics of circulating cells.<\/jats:p>","DOI":"10.1038\/s42003-024-06181-x","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T22:46:21Z","timestamp":1713653181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Leukemia circulation kinetics revealed through blood exchange method"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1847-4891","authenticated-orcid":false,"given":"Alex B.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia H.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Langenbucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Bray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Duquette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Goulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7380-0226","authenticated-orcid":false,"given":"Andrew A.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-3907","authenticated-orcid":false,"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6776-2163","authenticated-orcid":false,"given":"Michael T.","family":"Hemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5223-9433","authenticated-orcid":false,"given":"Scott R.","family":"Manalis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,20]]},"reference":[{"key":"6181_CR1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41568-021-00355-z","volume":"21","author":"AE Whiteley","year":"2021","unstructured":"Whiteley, A. E., Price, T. T., Cantelli, G. & Sipkins, D. A. Leukaemia: a model metastatic disease. Nat. Rev. Cancer 21, 461 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"6181_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000120756","volume":"2","author":"E Mathews","year":"2008","unstructured":"Mathews, E., Laurie, T., O\u2019Riordan, K. & Nabhan, C. Liver involvement with acute myeloid leukemia. Case Rep. Gastroenterol. 2, 121 (2008).","journal-title":"Case Rep. Gastroenterol."},{"key":"6181_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/978-0-387-69222-7_9","volume":"136","author":"ND Doolittle","year":"2007","unstructured":"Doolittle, N. D. Brain metastases in hematologic malignancies. Cancer Treat. Res 136, 169\u2013183 (2007).","journal-title":"Cancer Treat. Res"},{"key":"6181_CR4","doi-asserted-by":"crossref","unstructured":"Bross, I. D. J., Viadana, E. & Pickren, J. W. The metastatic spread of myeloma and leukemias in men. Virchows Arch. A Pathol. Anat. Histol. 365, 91\u2013101 (1975).","DOI":"10.1007\/BF00432382"},{"key":"6181_CR5","unstructured":"Madden, R. E. & Malmgren, R. A. Quantitative Studies on Circulating Cancer Cells in the Mouse | Cancer Research | American Association for Cancer Research. Cancer Res. 22, 62\u201366 https:\/\/aacrjournals.org\/cancerres\/article\/22\/1_Part_1\/62\/474851\/Quantitative-Studies-on-Circulating-Cancer-Cells (1962)."},{"key":"6181_CR6","first-page":"773","volume":"45","author":"IJ Fidler","year":"1970","unstructured":"Fidler, I. J. Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125I-5-Iodo-2\u2032 -deoxyuridine. JNCI: J. Natl Cancer Inst. 45, 773\u2013782 (1970).","journal-title":"JNCI: J. Natl Cancer Inst."},{"key":"6181_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.trecan.2015.07.006","volume":"1","author":"N Aceto","year":"2015","unstructured":"Aceto, N., Toner, M., Maheswaran, S. & Haber, D. A. En route to metastasis: circulating tumor cell clusters and epithelial-to-mesenchymal transition. Trends Cancer 1, 44\u201352 (2015).","journal-title":"Trends Cancer"},{"key":"6181_CR8","doi-asserted-by":"publisher","first-page":"8152","DOI":"10.1158\/1078-0432.CCR-04-1110","volume":"10","author":"S Meng","year":"2004","unstructured":"Meng, S. et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res 10, 8152\u20138162 (2004).","journal-title":"Clin. Cancer Res"},{"key":"6181_CR9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature17038","volume":"529","author":"J Massagu\u00e9","year":"2016","unstructured":"Massagu\u00e9, J. & Obenauf, A. C. Metastatic colonization by circulating tumour cells. Nature 529, 298\u2013309 (2016).","journal-title":"Nature"},{"key":"6181_CR10","first-page":"1075","volume":"164","author":"JH Morgan-Parkes","year":"1995","unstructured":"Morgan-Parkes, J. H. Metastases: mechanisms, pathways, and cascades. Adv. Clin. Med. 164, 1075\u20131082 (1995).","journal-title":"Adv. Clin. Med."},{"key":"6181_CR11","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1073\/pnas.1814102116","volume":"116","author":"B Hamza","year":"2019","unstructured":"Hamza, B. et al. Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer. Proc. Natl Acad. Sci. USA 116, 2232\u20132236 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6181_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-25917-5","volume":"12","author":"B Hamza","year":"2021","unstructured":"Hamza, B. et al. Measuring kinetics and metastatic propensity of CTCs by blood exchange between mice. Nat. Commun. 12, 1\u201311 (2021).","journal-title":"Nat. Commun."},{"key":"6181_CR13","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1182\/bloodadvances.2020001808","volume":"4","author":"Y Chen","year":"2020","unstructured":"Chen, Y. et al. Acute myeloid leukemia\u2013induced remodeling of the human bone marrow niche predicts clinical outcome. Blood Adv. 4, 5257\u20135268 (2020).","journal-title":"Blood Adv."},{"key":"6181_CR14","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-14-3379","volume":"75","author":"JA Kim","year":"2015","unstructured":"Kim, J. A. et al. Microenvironmental remodeling as a parameter and prognostic factor of heterogeneous leukemogenesis in acute myelogenous leukemia. Cancer Res 75, 2222\u20132231 (2015).","journal-title":"Cancer Res"},{"key":"6181_CR15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2017.08.001","volume":"32","author":"D Passaro","year":"2017","unstructured":"Passaro, D. et al. Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia. Cancer Cell 32, 324 (2017).","journal-title":"Cancer Cell"},{"key":"6181_CR16","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3324\/haematol.2019.246058","volume":"106","author":"B Kumar","year":"2021","unstructured":"Kumar, B. et al. Exosome-driven lipolysis and bone marrow niche remodeling support leukemia expansion. Haematologica 106, 1484 (2021).","journal-title":"Haematologica"},{"key":"6181_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.stem.2017.11.006","volume":"22","author":"D Duarte","year":"2018","unstructured":"Duarte, D. et al. Inhibition of endosteal vascular niche remodeling rescues hematopoietic stem cell loss in AML. Cell Stem Cell 22, 64\u201377.e6 (2018).","journal-title":"Cell Stem Cell"},{"key":"6181_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-019-1593-2","volume":"10","author":"S Berrazouane","year":"2019","unstructured":"Berrazouane, S. et al. Beta1 integrin blockade overcomes doxorubicin resistance in human T-cell acute lymphoblastic leukemia. Cell Death Dis. 10, 1\u201313 (2019).","journal-title":"Cell Death Dis."},{"key":"6181_CR19","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/sj.leu.2402608","volume":"16","author":"M Konopleva","year":"2002","unstructured":"Konopleva, M. et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 16, 1713\u20131724 (2002).","journal-title":"Leukemia"},{"key":"6181_CR20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3389\/fonc.2020.00775","volume":"10","author":"BFSS Scharff","year":"2020","unstructured":"Scharff, B. F. S. S., Modvig, S., Marquart, H. V. & Christensen, C. Integrin-mediated adhesion and chemoresistance of acute lymphoblastic leukemia cells residing in the bone marrow or the central nervous system. Front Oncol. 10, 775 (2020).","journal-title":"Front Oncol."},{"key":"6181_CR21","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1158\/1535-7163.MCT-06-0228","volume":"5","author":"Z Zeng","year":"2006","unstructured":"Zeng, Z. et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol. Cancer Ther. 5, 3113\u20133121 (2006).","journal-title":"Mol. Cancer Ther."},{"key":"6181_CR22","doi-asserted-by":"crossref","unstructured":"Barthel, S. R., Gavino, J. D., Descheny, L. & Dimitroff, C. J. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opinion on Therapeutic Targets 11, 1473\u20131491 (2007).","DOI":"10.1517\/14728222.11.11.1473"},{"key":"6181_CR23","doi-asserted-by":"crossref","unstructured":"Erbani, J., Tay, J., Barbier, V., Levesque, J. P. & Winkler, I. G. Acute Myeloid Leukemia Chemo-Resistance Is Mediated by E-selectin Receptor CD162 in Bone Marrow Niches. Front Cell Dev Biol. 8, 668 (2020).","DOI":"10.3389\/fcell.2020.00668"},{"key":"6181_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-15817-5","volume":"11","author":"V Barbier","year":"2020","unstructured":"Barbier, V. et al. Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance. Nat. Commun. 11, 1\u201315 (2020).","journal-title":"Nat. Commun."},{"key":"6181_CR25","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1182\/blood.2021010721","volume":"139","author":"DJ DeAngelo","year":"2022","unstructured":"DeAngelo, D. J. et al. Phase 1\/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood 139, 1135\u20131146 (2022).","journal-title":"Blood"},{"key":"6181_CR26","doi-asserted-by":"crossref","unstructured":"DeAngelo, D. J. et al. High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R\/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan. Blood 134, 2690 (2019).","DOI":"10.1182\/blood-2019-123744"},{"key":"6181_CR27","doi-asserted-by":"publisher","unstructured":"DeAngelo, D. J. et al. A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed\/refractory acute myeloid leukemia. J. Clin. Oncol. 37, https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS7066 (2019).","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7066"},{"key":"6181_CR28","doi-asserted-by":"crossref","unstructured":"Sison, E. A. R., McIntyre, E., Magoon, D. & Brown, P. Dynamic chemotherapy-induced upregulation of CXCR4 expression: A mechanism of therapeutic resistance in pediatric AML. Mol. Cancer Res. 11, 1004\u20131116 (2013).","DOI":"10.1158\/1541-7786.MCR-13-0114"},{"key":"6181_CR29","doi-asserted-by":"crossref","unstructured":"Gruszka, A. M., Valli, D., Restelli, C. & Alcalay, M. Adhesion deregulation in acute myeloid Leukaemia. Cells 8, 66 (2019).","DOI":"10.3390\/cells8010066"},{"key":"6181_CR30","doi-asserted-by":"crossref","unstructured":"Meads, M. B., Gatenby, R. A. & Dalton, W. S. Environment-mediated drug resistance: A major contributor to minimal residual disease. Nature Reviews Cancer 9, 665\u2013674 (2009).","DOI":"10.1038\/nrc2714"},{"key":"6181_CR31","doi-asserted-by":"crossref","unstructured":"Jacoby, E., Chien, C. D. & Fry, T. J. Murine Models of Acute Leukemia: Important Tools in Current Pediatric Leukemia Research. Front. Oncol. 4, 95 (2014).","DOI":"10.3389\/fonc.2014.00095"},{"key":"6181_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3390\/ijms20020453","volume":"20","author":"M Almosailleakh","year":"2019","unstructured":"Almosailleakh, M. & Schwaller, J. Murine Models of Acute Myeloid Leukaemia. Int. J. Mol. Sci. 20, 453 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"6181_CR33","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/bloodadvances.2017015610","volume":"2","author":"ERC Fiedler","year":"2018","unstructured":"Fiedler, E. R. C., Bhutkar, A., Lawler, E., Besada, R. & Hemann, M. T. In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1+ BCP-ALL. Blood Adv. 2, 1229\u20131242 (2018).","journal-title":"Blood Adv."},{"key":"6181_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01913-y","volume":"7","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia. Sci. Rep. 7, 1853 (2017).","journal-title":"Sci. Rep."},{"key":"6181_CR35","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1038\/leu.2013.135","volume":"27","author":"C Meyer","year":"2013","unstructured":"Meyer, C. et al. The MLL recombinome of acute leukemias in 2013. Leukemia 27, 2165\u20132176 (2013).","journal-title":"Leukemia"},{"key":"6181_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood.V97.1.4","volume":"97","author":"S Roumiantsev","year":"2001","unstructured":"Roumiantsev, S., De Aos, I. E., Varticovski, L., Maria, R. L. & Van Etten, R. A. The Src homology 2 domain of Bcr\/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood 97, 4\u201313 (2001).","journal-title":"Blood"},{"key":"6181_CR37","first-page":"511","volume":"95","author":"PR Galbraith","year":"1966","unstructured":"Galbraith, P. R. Studies on the longevity, sequestration and release of the leukocytes in chronic myelogenous leukemia. Can. Med Assoc. J. 95, 511\u2013521 (1966).","journal-title":"Can. Med Assoc. J."},{"key":"6181_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13045-021-01133-y","volume":"14","author":"B Zhang","year":"2021","unstructured":"Zhang, B. et al. Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML. J. Hematol. Oncol. 14, 122 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"6181_CR39","doi-asserted-by":"crossref","unstructured":"Jethava, Y. S. et al. Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia. Bone. Marrow. Transplant. 52, 1504\u20131511 (2017).","DOI":"10.1038\/bmt.2017.83"},{"key":"6181_CR40","doi-asserted-by":"crossref","unstructured":"Reshef, R. & Porter, D. L. Reduced-intensity conditioned allogeneic SCT in adults with AML. Bone. Marrow. Transplant. 50, 759\u2013769 (2015).","DOI":"10.1038\/bmt.2015.7"},{"key":"6181_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/bs.acr.2022.07.001","volume":"157","author":"E Ales","year":"2023","unstructured":"Ales, E. & Sackstein, R. The biology of E-selectin ligands in leukemogenesis. Adv. Cancer Res 157, 229\u2013250 (2023).","journal-title":"Adv. Cancer Res"},{"key":"6181_CR42","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10439-011-0507-y","volume":"40","author":"SD Chase","year":"2012","unstructured":"Chase, S. D., Magnani, J. L. & Simon, S. I. E-selectin ligands as mechanosensitive receptors on neutrophils in health and disease. Ann. Biomed. Eng. 40, 849 (2012).","journal-title":"Ann. Biomed. Eng."},{"key":"6181_CR43","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1039\/c5ib00284b","volume":"8","author":"J Shaw Bagnall","year":"2016","unstructured":"Shaw Bagnall, J. et al. Deformability-based cell selection with downstream immunofluorescence analysis. Integr. Biol. (U. Kingd.) 8, 654\u2013664 (2016).","journal-title":"Integr. Biol. (U. Kingd.)"},{"key":"6181_CR44","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/nature05741","volume":"446","author":"TP Burg","year":"2007","unstructured":"Burg, T. P. et al. Weighing of biomolecules, single cells and single nanoparticles in fluid. Nat. 446, 1066\u20131069 (2007).","journal-title":"Nat."},{"key":"6181_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms8070","volume":"6","author":"S Olcum","year":"2015","unstructured":"Olcum, S., Cermak, N., Wasserman, S. C. & Manalis, S. R. High-speed multiple-mode mass-sensing resolves dynamic nanoscale mass distributions. Nat. Commun. 6, 1\u20138 (2015).","journal-title":"Nat. Commun."},{"key":"6181_CR46","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/nbt.3697","volume":"34","author":"MM Stevens","year":"2016","unstructured":"Stevens, M. M. et al. Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat. Biotechnol. 34, 1161\u20131167 (2016).","journal-title":"Nat. Biotechnol."},{"key":"6181_CR47","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.3390\/cells10102712","volume":"10","author":"JK Hennigs","year":"2021","unstructured":"Hennigs, J. K., Matuszcak, C., Trepel, M. & K\u00f6rbelin, J. Vascular Endothelial Cells: Heterogeneity and Targeting Approaches. Cells 10, 2712 (2021).","journal-title":"Cells"},{"key":"6181_CR48","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/ar.1166","volume":"264","author":"S Inoue","year":"2001","unstructured":"Inoue, S. & Osmond, D. G. Basement membrane of mouse bone marrow sinusoids shows distinctive structure and proteoglycan composition: A high resolution ultrastructural study. Anat. Rec. 264, 294\u2013304 (2001).","journal-title":"Anat. Rec."},{"key":"6181_CR49","doi-asserted-by":"crossref","unstructured":"Kulkarni, R. & Kale, V. Physiological Cues Involved in the Regulation of Adhesion Mechanisms in Hematopoietic Stem Cell Fate Decision. Front. Cell. Dev. Biol. 8, 611 (2020).","DOI":"10.3389\/fcell.2020.00611"},{"key":"6181_CR50","doi-asserted-by":"crossref","unstructured":"Moore, M. A. S. Waking up HSCs: A new role for E-selectin. Nat. Med. 18, 1613\u20131614 (2012).","DOI":"10.1038\/nm.2992"},{"key":"6181_CR51","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.critrevonc.2019.01.024","volume":"137","author":"M Hassanshahi","year":"2019","unstructured":"Hassanshahi, M., Hassanshahi, A., Khabbazi, S., Su, Y. W. & Xian, C. J. Bone marrow sinusoidal endothelium as a facilitator\/regulator of cell egress from the bone marrow. Crit. Rev. Oncol. Hematol. 137, 43\u201356 (2019).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"6181_CR52","doi-asserted-by":"crossref","unstructured":"Mosteo, L. et al. The Dynamic Interface Between the Bone Marrow Vascular Niche and Hematopoietic Stem Cells in Myeloid Malignancy. Front. Cell. Dev. Biol. 9, 635189 (2021).","DOI":"10.3389\/fcell.2021.635189"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06181-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06181-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06181-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T22:47:14Z","timestamp":1713653234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06181-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6181"],"URL":"https:\/\/doi.org\/10.1038\/s42003-024-06181-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.09.03.556043","asserted-by":"object"}]},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,20]]},"assertion":[{"value":"13 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: A.B.M. is an employee of RA Capital Management. D.R.G. is an employee of Vor Biopharma Inc. D.M.W. is an employee of Merck and Co., owns equity in Merck and Co., Bantam, Ajax, and Travera, received consulting fees from Astra Zeneca, Secura, Novartis, and Roche\/Genentech, and received research support from Daiichi Sankyo, Astra Zeneca, Verastem, Abbvie, Novartis, Abcura, and Surface Oncology. A.A.L. received research funding from Abbvie and Stemline therapeutics, and consulting fees from Cimeio Therapeutics, IDRx, Jnana Therapeutics, ProteinQure, and Qiagen, and has equity as an advisor for Medzown. S.R.M. owns equity in Travera and Affinity Biosensors. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"483"}}